Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Study Implicates Epstein-Barr Virus in 7 Autoimmune Diseases

Mary Beth Nierengarten  |  Issue: October 2019  |  October 18, 2019

Kateryna Kon / shutterstock.com

Kateryna Kon / shutterstock.com

The identification of specific transcription factors linked to the Epstein-Barr virus (EBV) provides new information on the molecular mechanisms underlying the link between EBV and autoimmune disease.

A recently published study, “Transcrip­tion Factors Operate Across Disease Loci, with EBNA2 Implicated in Auto­immunity,” co-led by John B. Harley, MD, PhD; Leah C. Kottyan, PhD; and Matthew T. Weirauch, PhD, at the Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center, Ohio, found EBNA2, a protein produced by Epstein-Barr, binds to several locations along the human genome—locations that are associated with seven autoimmune diseases: systemic lupus erythematosus (SLE), multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, inflammatory bowel disease, celiac disease and type 1 diabetes.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Harley, director of the Center for Autoimmune Genomics and Etiology and professor of pediatrics and medicine at the University of Cincinnati, where he holds the David Glass Endowed Chair, says this finding is consistent with the possibility the Epstein-Barr virus causes these seven autoimmune diseases for at least some patients with these diseases.

“There were strong hints [of this] previously,” he says, “but the extent of the relationship was not known.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“The link between EBV and auto­immunity has been suspected but remains controversial,” says Peter A. Nigrovic, MD, associate professor of medicine at Harvard Medical School, director of the Center for Adults with Pediatric Rheumatic Illness and director of the Joint Biology Consortium of Boston Children’s Hospital and Brigham and Women’s Hospital, Boston, commenting on the study. “This study integrates a vast amount of data to identify a genetic explanation for the connection. By pro­viding a candidate mechanism, Harley and colleagues help render the epidemiologic evidence behind the association between EBV and autoimmunity more readily comprehensible.”

Uncovering Molecular Mechanisms

In the study, investigators developed and used two novel informatics tools. As explained in an article by Dr. Weirauch, a computational biologist, one of the tools is a new computational method for discovering disease-driving mechanisms.2 Called the Regulatory Element Locus Intersector, the method is an algorithm that estimates the significance of the intersection between disease-causing variants and DNA sequence. This tool allowed investigators to identify particular proteins occupying disease risk loci. Once these proteins were identified, the investigators used the second novel tool, the Measurement of Allelic Ratios Informatics Operator (MARIO), to provide insight into the molecular mechanisms of disease. Using MARIO, the investigators were able to show examples of a possible genetic role for the transcription factors linked to various diseases, Dr. Weirauch states in the article.

By using these tools, the investigators were able to show that transcription factors and cofactors are often concentrated in the risk loci of diseases and physiological phenotypes are frequently expected by chance, according to Dr. Harley.

Specifically, the study identified 2,264 relationships be­tween hundreds of transcription factors and 94 phenotypes. For example, the study found the Epstein-Barr virus EBNA2 protein and many clustering human transcription factors occupy nearly half of systemic lupus erythematosus risk loci. The EBNA2 protein and clustering human transcription factors also occupy multiple other auto­immune diseases, including rheumatoid arthritis, multiple sclerosis, type 1 diabetes, juvenile idiopathic arthritis, inflammatory bowel disease and celiac disease. Overall, this association with EBNA2 and these autoimmune diseases demonstrates a gene-environment interaction of these diseases.

“The study by Dr. Harley and colleagues indicates the genes targeted by EBV are disproportionately ones that alter risk of autoimmune diseases, including lupus and rheumatoid arthritis,” says Dr. Nigrovic. “This finding, therefore, provides a new mechanistic link between EBV infection and autoimmune diseases.”

Some of the results for systemic lupus erythematosus from the recent study published in Nature Genetics are presented in Figure 1.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsResearch Rheum Tagged with:Epstein-Barr virus (EBV)

Related Articles

    Rheumatology Case Report: Concomitant Lupus with Features of Scleroderma, Castleman Disease

    July 11, 2016

    We report a case of a 27-year-old woman who was initially diagnosed with systemic lupus erythematosus (SLE), had features of scleroderma and was subsequently found to have lymph node biopsy consistent with multicentric Castleman disease (MCD). She also had serologic evidence of acute Epstein-Barr virus (EBV) infection (vs. reactivation of EBV). The occurrence of MCD…

    What’s the Role of Epstein-Barr Virus Reactivation in Lupus Development?

    November 12, 2020

    A strong association between Epstein-Barr virus (EBV) infections and systemic lupus erythematosus (SLE) has been known since the 1970s. Although the etiology of SLE is not fully established, multiple genetic factors and polymorphisms in genes involved in the immune system have been implicated, with environmental factors also contributing to the development of this complex condition….

    Genome-Wide Association Studies of SLE

    February 12, 2011

    What do these studies tell us about disease mechanisms in lupus?

    Search for Infectious Triggers of Rheumatic Disease Could Yield Options to Block Process

    January 19, 2016

    SAN FRANCISCO—Two hundred years ago, physicians knew nothing about what caused various forms of arthritis. Today, we have more clues about what may trigger rheumatic diseases, but still can’t pinpoint the culprits that set scores of inflammatory conditions in motion. Researchers discussed some of the background and recent findings that point to what immunologists call…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences